Back
Supreme Court Refuses Plea Against Kerala Distribution of Homeopathic Drug Without
The on Friday declined to entertain a petition challenging the of the homoeopathic drug Arsenicum Album in Kerala without prior . The drug had been promoted as an “immunity booster” during the COVID-19 pandemic, and the petitioner alleged that its distribution violated the clinical testing protocols mandated under the .
A Bench comprising Chief Justice Surya Kant and Justices Joymalya Bagchi and V. Mohana heard , who argued that homoeopathic medicines are not exempt from the requirement of . The Court, however, noted the extraordinary circumstances of the pandemic and suggested that the petitioner file a fresh, if it wished to challenge the broader policy of administering homoeopathic drugs without .
Background: The Pandemic and the Drug
During the height of the COVID-19 pandemic in 2020, the , in coordination with the , widely distributed Arsenicum Album as a preventive and immunity-boosting remedy. The drug was administered to large populations, including children, without undergoing the standard required for pharmaceutical products. The had issued guidelines supporting the use of certain homoeopathic preparations during the health emergency.
The petitioner, through Senior Advocate Grover, contended that this bypassed the legal framework designed to ensure drug safety and efficacy. The plea specifically questioned whether the drug had been subject to any or other before being rolled out on such a scale.
The Petition and Arguments
Appearing before the Bench, Mr. Grover clarified that the petition did not challenge the efficacy or legitimacy of homoeopathy as a system of medicine. Instead, it focused on a narrow legal question: whether the distribution of Arsenicum Album complied with the clinical trial protocols prescribed under the Drugs and Cosmetics Act.
“Homeopathic medicines are also subject to under the Drugs and Cosmetics Act. It is our case that there were no trials. That is the only issue,” Mr. Grover submitted.
He further argued that while the emergency situation during the pandemic might have justified temporary relaxations, the continued administration of the drug even after the crisis had subsided was unlawful. “The issue requires examination as the is allegedly continuing to administer Arsenicum Album to children,” he added.
Court’s Observations
The Bench responded to the arguments with contextual observations. CJI Surya Kant remarked, “During COVID, all kinds of advisories were issued. Everybody was caught unawares. Nobody knew what was to be done.” This appeared to acknowledge the unprecedented nature of the public health crisis and the difficulty of applying standard regulatory frameworks in real time.
Justice Joymalya Bagchi drew attention to parallel relaxations granted for allopathic medicines during the pandemic. “Similar relaxations were made during the pandemic even in relation to allopathic medicines. Medical authorities across the world shortened the timelines for experimentation and approval of vaccines in view of the global emergency,” he observed.
Mr. Grover, however, insisted that the petition was not about the pandemic alone. He pointed to the ongoing use of the drug under the AYUSH guidelines issued by the , which continued to operate outside the Drugs and Cosmetics Act’s trial requirements.
Ultimately, the Court declined to examine the continued use of Arsenicum Album in the present proceedings. CJI Kant stated, “Not here. File an ,” making clear that the broader issue could be raised separately.
Legal Analysis: Balancing and
This case highlights a fundamental tension in pharmaceutical law: the need for robust clinical trial protocols versus the flexibility required during public health emergencies. The , through its various schedules and rules, mandates that all drugs—including homoeopathic preparations—undergo adequate testing before being marketed or administered to the public. However, the pandemic saw widespread deviations from these norms, as governments across the world fast-tracked approvals for vaccines and therapeutics.
The Supreme Court’s refusal to entertain the petition does not necessarily endorse the legality of the drug’s distribution. Rather, it reflects the Court’s reluctance to adjudicate a complex regulatory issue without a focused challenge and comprehensive record. By directing the petitioner to file an , the Bench preserved the possibility of a future specifically targeting the AYUSH guidelines and the state’s reliance on them.
Broader Implications for Pharmaceutical Regulation
The decision has significant implications for the regulation of homoeopathic and other alternative medicines in India. The operates under a separate legal framework, and questions have long been raised about the scientific rigour applied to drugs marketed under its purview. If a fresh petition is filed and admitted, the Court may be called upon to interpret the extent to which the Drugs and Cosmetics Act applies to homoeopathic drugs, and whether the exercised during the pandemic can justify ongoing non-compliance.
Legal professionals will also note the Court’s emphasis on the need for an independent inquiry. CJI Kant observed that determining whether homoeopathic medicines were being permitted without complying with the Drugs and Cosmetics Act would require fact-finding that was beyond the scope of the present petition. This leaves the door open for a more comprehensive of the ’s guidelines and their intersection with mainstream drug regulation.
Conclusion
The Supreme Court’s decision to refuse the plea does not close the door on accountability but rather reframes the legal battlefield. By inviting a separate petition, the Court has signalled that the issue of clinical trial compliance for homoeopathic drugs warrants closer scrutiny. For the legal community, this case serves as a reminder of the delicate balance between and public health exigencies. As the aftermath of the pandemic continues to reshape legal norms, the fate of Arsenicum Album —and the regulatory framework governing alternative medicines—remains an evolving question.
